Evidence map›Paper›PMID 41351144›Full record

ArticleBMC pulmonary medicine2025

Gender-age-physiology stage and body mass index are useful predictors of nintedanib discontinuation and prognosis in patients with idiopathic pulmonary fibrosis and progressive fibrotic interstitial lung diseases.

Kai Yazaki, Masashi Matsuyama, Hiroaki Satoh, Kunihiko Miyazaki, Naoki Arai, Yukio Ishii, Takeo Endo, Takayuki Kaburagi, Takeshi Kawakami, Hiroaki Iijima and 5 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kai YazakiDepartment of Respiratory Medicine, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Masashi MatsuyamaDepartment of Respiratory Medicine, Institute of Medicine, University of Tsukuba, Tsukuba, Japan. mmatsuyama@md.tsukuba.ac.jp.
Hiroaki SatohDepartment of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Japan.
Kunihiko MiyazakiDepartment of Respiratory Medicine, Ryugasaki Saiseikai Hospital, Ryugasaki, Japan.
Naoki AraiDepartment of Respiratory Medicine, National Hospital Organization Ibarakihigashi National Hospital, Tokai, Japan.
Yukio IshiiDepartment of Respiratory Medicine, National Hospital Organization Ibarakihigashi National Hospital, Tokai, Japan.
Takeo EndoDepartment of Respiratory Medicine, National Hospital Organization Mito Medical Center, Ibarakimachi, Japan.
Takayuki KaburagiDepartment of Respiratory Medicine, Ibaraki Prefectural Central Hospital, Kasama, Japan.
Takeshi KawakamiDepartment of Respiratory Medicine, Kobari General Hospital, Noda, Japan.
Hiroaki IijimaDepartment of Respiratory Medicine, Tsukuba Medical Center Hospital, Tsukuba, Japan.
Toshiaki MotegiDepartment of Respiratory Medicine, Ibaraki Seinan Medical Center Hospital, Sakai, Japan.
Shigen HayashiDepartment of Respiratory Medicine, Ibaraki Seinan Medical Center Hospital, Sakai, Japan.
Norihiro KikuchiDepartment of Respiratory Medicine, National Hospital Organization Kasumigaura Medical Center, Tsuchiura, Japan.
Tohru SakamotoDepartment of Respiratory Medicine, Tsukuba Memorial Hospital, Tsukuba, Japan.
Nobuyuki HizawaDepartment of Respiratory Medicine, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionData on risk factors for discontinuation of nintedanib in patients with interstitial lung diseases (ILDs) are limited. The differences in tolerability between patients with idiopathic pulmonary fibrosis (IPF) and those with progressive fibrotic interstitial lung diseases (PF-ILDs), as well as between different severities, remain unclear. The aim of this study was to investigate the clinical characteristics associated with discontinuation of nintedanib, including severity and the presence of IPF or PF-ILDs, in patients with ILDs.

methodsA multicenter, retrospective study was conducted. Patients with IPF and PF-ILDs who had been treated with nintedanib from August 2015 to December 2023 were analyzed. Severity at baseline was assessed using the gender-age-physiology (GAP) model. Clinical characteristics were compared between the nintedanib discontinuation within 12 months group and the nintedanib continuation over 12 months group.

resultsA total of 212 ILD patients were included in the analysis, of whom 165 (77.8%) had IPF, and 47 (22.2%) had PF-ILDs. Fifty-five (25.9%) patients discontinued nintedanib within 12 months. The risk of nintedanib discontinuation was associated with higher GAP stage, lower body mass index (BMI), and no dose reduction. Patients with a higher GAP stage and lower BMI also had poor overall survival. There were no significant differences between IPF and PF-ILDs in both nintedanib discontinuation and mortality.

conclusionsGAP stage and BMI can be useful for predicting prognosis and future nintedanib discontinuation in patients with IPF and PF-ILDs. Nintedanib treatment may be considered in patients with IPF and PF-ILDs in an earlier stage of the disease.

Indexed as

Body Mass IndexIdiopathic Pulmonary FibrosisIndolesLung Diseases, InterstitialWithholding TreatmentAgedAge FactorsDisease ProgressionFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesRisk FactorsSeverity of Illness IndexIndolesnintedanibIdiopathic pulmonary fibrosisNintedanibProgressive fibrotic interstitial lung disease

Identifiers

PMID41351144
PMCPMC12751843

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.